NRXP

NRXP is a pre-commercial CNS drug developer whose own auditors and management state, in plain language, that 'substantial doubt exists about the Company's ability to continue as a going concern' for at least twelve months. The numbers make the reason obvious: FY2025 revenue was just $1.23M against a $28.6M net loss (net margin -2,336%), operating cash flow was -$14.1M, and the company ended the year with only $7.80M of cash, a $15.9M stockholders' deficit, a $19.7M working-capital deficit, and a $306.9M accumulated deficit. This is not a business with a valuation problem; it is a business fighting for survival.

Survival so far has come entirely from selling stock. Shares outstanding jumped 95.5% YoY to 33.1M as management tapped a reinstated $20M ATM ($6.54M raised), an 8%-OID Anson note tranche ($5.0M), a $1.65/share registered direct ($6.2M), and warrant exercises ($3.09M). The MD&A is explicit that funding the pipeline will require yet more 'equity or debt financing or refinancing,' which 'could result in additional dilution.' A retail buyer at $3.87 is therefore standing in front of a continuous dilution machine, and even that machine only bought roughly half a year of runway at the FY2025 burn rate.